We found that, compared with grade II–III glioma (LGG), the expression levels of SPATS2L were higher in GBM patients in the GSE4412, GSE16011, GSE43378, GSE83294, TCGA, and CGGA datasets (Figure 6C). This evidence concerns the gene SPATS2L and central nervous system cancer.